Cel-Sci Corporation (NASDAQ: CVM) stands out in the biotechnology sector with an eye-catching potential upside of 823.91%, according to recent analyst ratings. This clinical-stage biotech firm, headquartered in Vienna, Virginia, is focused on harnessing the immune system to develop innovative cancer treatments and therapies for other diseases. Its recent advancements, coupled with a highly favorable analyst outlook, make it a compelling option for risk-tolerant investors seeking exposure to the healthcare sector.
#### Intriguing Valuation and Price Dynamics
With a market capitalization of $38.68 million, Cel-Sci is a small-cap entity, often characterized by high volatility but substantial growth opportunities. Its current share…
